PDCD1 and central nervous system cancer: TLR signaling was discovered to enhance the expression of PD-1 and PD-L1 on glioma cells [183], indicating that TLR-based therapies combined with checkpoint inhibitor can be beneficial for treating against PD-1/PD-L1-expressing tumor cells.